25934 Bimekizumab efficacy for moderate to severe plaque psoriasis across patient subgroups: Pooled results from 3 multicenter, randomized, double-blinded phase 3 trials
Strober B, Warren R, Foley P, Gooderham M, Thaçi D, Cullen E, Cioffi C, Peterson L, Madden C, Armstrong A. 25934 Bimekizumab efficacy for moderate to severe plaque psoriasis across patient subgroups: Pooled results from 3 multicenter, randomized, double-blinded phase 3 trials. Journal Of The American Academy Of Dermatology 2021, 85: ab76. DOI: 10.1016/j.jaad.2021.06.329.Peer-Reviewed Original ResearchDouble-blinded phase 3 trialSevere plaque psoriasisPhase 3 trialPlaque psoriasisPatient subgroupsMulticenterPsoriasis